Injectable Methotrexate Product Now Available
01/17/2014
For patients who do not tolerate oral methotrexate for psoriasis, a new recently approved injectable methotrexate product is now available from Antares Pharma. Approved in October 2013 for the subcutaneous methotrexate product for once weekly self-administration, Otrexup is indicated for use in adults who need symptomatic control of severe recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy. It comes with a single dose, disposable auto injector that increases ease of use for patients.
“OTREXUP provides an attractive new option that may benefit patients who have had an inadequate response to or are intolerant of oral MTX,” said Paul K. Wotton, PhD, President and Chief Executive Officer, Antares. “OTREXUP is an easy-to-use auto injector that delivers greater blood levels of medication than oral MTX. OTREXUP could extend the use and benefits of MTX and potentially delay or avoid the use of other more expensive treatment options in some patients.”
“OTREXUP provides an attractive new option that may benefit patients who have had an inadequate response to or are intolerant of oral MTX,” said Paul K. Wotton, PhD, President and Chief Executive Officer, Antares. “OTREXUP is an easy-to-use auto injector that delivers greater blood levels of medication than oral MTX. OTREXUP could extend the use and benefits of MTX and potentially delay or avoid the use of other more expensive treatment options in some patients.”